PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 4, 2026European Heart Journal - Case Reports0 citationsOpen Access

Case report: VA-ECMO as a Bridge to collapse in Carcinoid Heart Disease

View Full Paper
AHAna Alañón HernándezJRJavier Tobar RuizJFJose Francisco Gil Fernandez

Key Points

  • This case report aims to illustrate the risks associated with using VA-ECMO in patients with carcinoid heart disease and cardiogenic shock.
  • Descriptive case report of a patient with suspected neuroendocrine tumor and severe carcinoid heart disease
  • VA-ECMO initiated for refractory cardiogenic shock
  • Multidisciplinary team approach for diagnosis and management
  • Patient experienced abrupt hemodynamic collapse after VA-ECMO initiation
  • Progressed to multiorgan failure, leading to death
  • Highlights the potential deleterious effects of VA-ECMO in carcinoid physiology

Abstract

Abstract Background Carcinoid heart disease is a rare complication of neuroendocrine tumors caused by chronic exposure to vasoactive substances, leading to progressive valvular dysfunction and right heart failure. The use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) in this context remains controversial, as it may exacerbate carcinoid crisis by bypassing the pulmonary metabolism of these vasoactive mediators. Case summary We describe a patient with clinical suspicion of a neuroendocrine tumor and severe carcinoid heart disease who developed refractory cardiogenic shock. VA-ECMO was initiated as rescue support but resulted in a abrupt hemodynamic collapse, the patient subsequently progressed to multiorgan failure and died. This case illustrates the paradoxical and potentially deleterious effects of extracorporeal support in the setting of carcinoid physiology. Discussion In the setting of a carcinoid crisis with cardiogenic shock secondary to right ventricular failure, VA-ECMO may appear as a potential option for hemodynamic support. However, by reducing pulmonary blood flow—and consequently the degradation of vasoactive substances—its use may worsen the patient’s clinical condition. Therefore, a multidisciplinary approach involving cardiology, acute cardiac care, intensive care, oncology, gastroenterology, endocrinology, and pathology teams is essential, both in diagnosis and management.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hernández et al. (2026) studied this question.

synapsesocial.com/papers/69f836aa3ed186a739980e86https://doi.org/10.1093/ehjcr/ytag272
Ask AI
Helpful
Bookmark
Share
View Full Paper